Department of Mechanical Engineering, Faculty of Engineering, Technology and Built Environment, 125743UCSI University, Kuala Lumpur, Malaysia.
Faculty of Clinical Research, Central Research Facility, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221145246. doi: 10.1177/15330338221145246.
Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and have a higher recurrence rate, greater metastatic potential, and lower overall survival rate than those of other breast cancers. Treatment of triple-negative breast cancer is challenging; molecular-targeted therapies are largely ineffective and there is no standard treatment. In this review, we evaluate current attempts to classify triple-negative breast cancers based on their molecular features. We also describe promising treatment methods with different advantages and discuss genetic biomarkers and other prediction tools. Accurate molecular classification of triple-negative breast cancers is critical for patient risk categorization, treatment decisions, and surveillance. This review offers new ideas for more effective treatment of triple-negative breast cancer and identifies novel targets for drug development.
乳腺癌是最常见的恶性肿瘤，也是女性癌症相关死亡的第二大常见原因。三阴性乳腺癌不表达雌激素受体、孕激素受体或人表皮生长因子受体 2，其复发率更高，转移潜能更大，总生存率低于其他乳腺癌。三阴性乳腺癌的治疗具有挑战性；分子靶向治疗效果大多不佳，也没有标准的治疗方法。在这篇综述中，我们评估了目前基于分子特征对三阴性乳腺癌进行分类的尝试。我们还描述了具有不同优势的有前途的治疗方法，并讨论了遗传生物标志物和其他预测工具。准确的三阴性乳腺癌分子分类对于患者风险分类、治疗决策和监测至关重要。本综述为更有效地治疗三阴性乳腺癌提供了新的思路，并为药物开发找到了新的靶点。
